Carmel Lynch
Senior Vice President
Pharmaceutical
Oxford BioTherapeutics
Switzerland
Biography
Dr. Lynch has over 20 years' R&D experience in the international biotechnology industry. Prior to joining OBT, she was Senior Director at Seattle Genetics where she led the non-clinical science and clinical pharmacology work for the approval of the oncology antibody-drug conjugate ADCETRIS. Previously, she was Director of Non-clinical Development at Corixa and held positions at Targeted Genetics Corporation, including Director of Pre-clinical Biology. Dr. Lynch holds a PhD in pharmacology from University College Dublin, and conducted post-doctoral research at the Fred Hutchinson Cancer Research Centre in Seattle.
Research Interest
Genetics, Pharmacology
